Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis
2023 · BMC Medicine · 26 citations
https://doi.org/10.1186/s12916-023-02861-3
H
Hongyuan Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
55
Papers
1.7K
Citations
12
h-index
13
i10-index
Hongyuan Wang is an academic researcher from Peking University. The author has contributed to research in topics: Hepatitis B Virus Studies & Hepatitis C virus research & Liver Disease Diagnosis and Treatment. The author has an h-index of 12, co-authored 47 publications.
ORCID: 0000-0002-9330-5940Papers by this author
worksPredicting nosocomial lower respiratory tract infections by a risk index based system
2017 · Scientific Reports · 7 citations
https://doi.org/10.1038/s41598-017-15765-z
On-line identification of 4″-isovalerylspiramycin I in the genetic engineered strain of S. spiramyceticus F21 by liquid chromatography with electrospray ionization tandem mass spectrometry, ultraviolet absorbance detection and nuclear magnetic resonance spectrometry
2010 · Journal of Chromatography A · 5 citations
https://doi.org/10.1016/j.chroma.2009.12.072
Sa1640 LONG-TERM SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS; FINAL 8-YEAR RESULTS OF 2 PHASE 3 STUDIES
2024 · Gastroenterology · 0 citations
https://doi.org/10.1016/s0016-5085(24)04156-8
Safety and efficacy of tenofovir alafenamide in preventing hepatitis B virus recurrence after liver transplantation in patients with chronic kidney disease maintained on tenofovir disoproxil fumarate: Results from a phase 2 randomized trial
2025 · American Journal of Transplantation · 0 citations
https://doi.org/10.1016/j.ajt.2025.09.012
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat